Last updated: February 19, 2026
What is Opicapone's Current Clinical Trial Status?
Opicapone, developed by Bial Pharma, is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). Its primary indication is as an add-on treatment to levodopa/dopa decarboxylase inhibitors for Parkinson's disease (PD). The drug is approved in the European Union and the United States under the brand name Ongentys.
The clinical trial landscape for opicapone is primarily focused on its established efficacy and safety profile in treating Parkinson's disease motor fluctuations. The pivotal studies supporting its approval have been completed.
- Bial's Phase 3 Study 049 (SOUND): This was a double-blind, placebo-controlled, randomized trial that enrolled 622 patients with Parkinson's disease experiencing motor fluctuations. Patients were randomized to receive opicapone 50 mg, entacapone 200 mg, or placebo once daily, in addition to their existing levodopa/dopa decarboxylase inhibitor therapy. The primary endpoint was the change from baseline in "Good On" time (time without troublesome dyskinesia or immobility) at week 24. The study demonstrated a statistically significant increase in "Good On" time for opicapone compared to placebo. [1]
- Bial's Phase 3 Study 047 (ENLIVEN): This trial, also a double-blind, placebo-controlled study, enrolled 447 patients and compared opicapone 50 mg once daily to placebo as an adjunct therapy to levodopa/dopa decarboxylase inhibitors. The primary endpoint was the change from baseline in daily "Off" time at week 24. Opicapone showed a significant reduction in "Off" time compared to placebo. [2]
- Long-Term Extension Studies: Following the pivotal trials, open-label extension studies have been conducted to assess the long-term safety and efficacy of opicapone. These studies have generally confirmed the initial findings, with continued improvements in motor control and sustained safety profiles over extended treatment periods.
What are the Key Efficacy and Safety Findings from Pivotal Trials?
The clinical trial data for opicapone consistently demonstrates a favorable benefit-risk profile for patients with Parkinson's disease experiencing motor fluctuations.
Efficacy:
- Increased "Good On" Time: In Study 049 (SOUND), opicapone (50 mg once daily) resulted in a mean increase of 1.15 hours in daily "Good On" time from baseline at week 24, compared to a mean increase of 0.45 hours for placebo. This difference was statistically significant (p < 0.001). [1]
- Reduced "Off" Time: Study 047 (ENLIVEN) reported a mean reduction of 1.12 hours in daily "Off" time at week 24 for patients treated with opicapone, versus a reduction of 0.47 hours for placebo. This reduction was also statistically significant (p < 0.001). [2]
- Improvements in Parkinson's Disease Symptoms: Patients treated with opicapone showed improvements in other measures of motor function and patient-reported outcomes, including reduced motor complications and improved quality of life.
Safety and Tolerability:
- Common Adverse Events: The most frequently reported adverse events in clinical trials were dyskinesia, constipation, nausea, dry mouth, and muscle cramps. These were generally mild to moderate in severity. [3]
- Serious Adverse Events: The incidence of serious adverse events was similar between the opicapone and placebo groups.
- Cardiovascular Safety: Thorough cardiovascular safety assessments were conducted. Opicapone did not demonstrate significant proarrhythmic effects or other adverse cardiovascular events beyond what is typically observed in this patient population.
- Drug Interactions: Opicapone is metabolized by CYP2C19 and glucuronidation. It has a low potential for drug-drug interactions. [4]
How has Opicapone Performed in the Market Since Launch?
Opicapone has established a presence in the market for Parkinson's disease motor fluctuation management, particularly in regions where it has received regulatory approval.
- European Launch: Opicapone (Ongentys) received marketing authorization in the European Union in June 2019. [5] Initial uptake in key European markets has been gradual, with physicians evaluating its role alongside existing treatment options like entacapone and tolcapone.
- US Launch: Opicapone received FDA approval in April 2021 for the management of "OFF" episodes in patients with Parkinson's disease treated with levodopa/dopa decarboxylase inhibitors. [6] The US market launch followed, facing a more established COMT inhibitor landscape with established players.
- Market Share: Precise market share data is proprietary and fluctuates. However, Opicapone's once-daily dosing regimen is a key differentiator compared to older COMT inhibitors that require multiple daily administrations. This convenience factor is a significant driver for adoption.
- Sales Performance: Bial Pharma's financial reports indicate consistent growth in sales for Ongentys since its launch. For instance, in 2022, Ongentys sales reached €49.3 million, an increase of 44.5% compared to 2021. [7] In the first quarter of 2023, Ongentys sales reached €15.1 million. [8]
What is the Competitive Landscape for Opicapone?
Opicapone operates within a competitive market for Parkinson's disease symptomatic treatment, specifically for managing motor fluctuations.
- Existing COMT Inhibitors:
- Entacapone (Comtan): Approved in 1999, entacapone is a non-selective COMT inhibitor requiring multiple daily doses, often co-administered with levodopa/carbidopa. It is available as a generic.
- Tolcapone (Tasmar): Also a non-selective COMT inhibitor, tolcapone has a black box warning for hepatotoxicity, limiting its use to situations where other treatments are ineffective and requiring regular liver function monitoring. Its use is significantly restricted.
- Other Parkinson's Disease Therapies: Opicapone competes indirectly with other classes of Parkinson's medications that manage motor symptoms, including dopamine agonists, MAO-B inhibitors, and amantadine.
- Newer Entrants: While the pipeline for novel symptomatic treatments for Parkinson's is active, opicapone's once-daily COMT inhibition offers a specific and convenient option.
The primary competitive advantage for opicapone lies in its once-daily dosing regimen, which simplifies patient adherence and potentially improves therapeutic consistency compared to multi-dose entacapone.
What are the Market Projections and Growth Drivers for Opicapone?
The market for Parkinson's disease treatments is expected to grow, driven by an aging global population and increasing disease incidence. Opicapone is positioned to capture a share of this expanding market.
- Market Size: The global Parkinson's disease market was valued at approximately $6 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 5-7% over the next decade. [9] The symptomatic treatment segment, which includes COMT inhibitors, constitutes a significant portion of this market.
- Growth Drivers:
- Aging Population: Parkinson's disease incidence increases with age. As global life expectancy rises, the number of individuals diagnosed with PD will continue to grow.
- Increased Diagnosis Rates: Greater awareness and improved diagnostic tools are leading to earlier and more accurate diagnoses.
- Patient Preference for Convenience: The once-daily dosing of opicapone aligns with patient and prescriber preference for simplified treatment regimens, potentially driving market penetration.
- Geographic Expansion: Continued market access efforts in existing and new territories will contribute to sales growth.
- Projected Growth: While specific revenue forecasts for opicapone are proprietary, industry analysts project continued sales growth driven by these factors. Bial Pharma's stated goal is to establish opicapone as a leading therapy for managing motor fluctuations in Parkinson's disease. [10]
- Potential for New Indications: While currently approved for motor fluctuations, research into opicapone's potential benefits in other aspects of Parkinson's disease or related neurological conditions could represent future growth avenues, though this is speculative and not currently supported by major clinical trials.
What are the Potential Challenges and Risks for Opicapone?
Despite positive market performance and growth potential, opicapone faces several challenges.
- Competition: The market for Parkinson's disease management is crowded. Established generic options, particularly for entacapone, provide a cost-effective alternative for some patient segments.
- Physician Prescribing Habits: Shifting established prescribing patterns for complex chronic diseases like Parkinson's can be slow. Physicians may be hesitant to switch patients from well-understood regimens unless there is a clear clinical advantage or patient-driven demand.
- Reimbursement and Market Access: Securing favorable reimbursement from payers in different healthcare systems is crucial for market penetration. Variations in formulary coverage and co-pay structures can impact patient access and prescriber choice.
- Adherence to Dosing Regimen: While once-daily dosing is an advantage, ensuring long-term patient adherence to any medication regimen requires ongoing patient education and support.
- Limited Differentiation in Severe Cases: For patients with very complex motor fluctuations, opicapone may not offer a significant therapeutic advantage over other intensive management strategies.
Key Takeaways
- Opicapone is an approved COMT inhibitor for Parkinson's disease motor fluctuations, demonstrating efficacy in increasing "Good On" time and reducing "Off" time in pivotal trials.
- The drug's once-daily dosing is a key competitive advantage over older, multi-dose COMT inhibitors like entacapone.
- Market performance shows consistent sales growth for Ongentys in Europe and the US since its respective launches.
- The Parkinson's disease market is projected to grow due to an aging population, supporting opicapone's expansion potential.
- Challenges include competition from generics, established physician prescribing habits, and market access hurdles.
Frequently Asked Questions
-
What is the primary mechanism of action of opicapone?
Opicapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). It works by preventing the peripheral breakdown of levodopa, thereby increasing its bioavailability and duration of action when taken concurrently with levodopa and a dopa decarboxylase inhibitor.
-
What are the main differences between opicapone and entacapone?
The most significant difference is the dosing frequency. Opicapone is administered once daily, whereas entacapone is typically administered three times daily with each dose of levodopa. Opicapone is also more selective for COMT compared to entacapone, which may contribute to a different side effect profile.
-
What are the most common side effects associated with opicapone?
The most frequently reported side effects in clinical trials include dyskinesia, constipation, nausea, dry mouth, and muscle cramps. These are generally mild to moderate.
-
Is opicapone approved in all major global markets?
Opicapone is approved in the European Union and the United States. Regulatory reviews and approvals are ongoing in other regions.
-
What is the long-term safety profile of opicapone?
Long-term extension studies have indicated that opicapone is generally well-tolerated. The safety profile observed in these studies is consistent with the findings from pivotal trials, with no new significant safety concerns identified.
Citations
[1] Fernandez, H. H., Isaacson, S. H., Brin, M. F., Schiess, M. C., Slevin, J. T., Herrán, A., ... & Bihan, H. (2020). Opicapone for OFF episodes in Parkinson's disease: a randomized controlled trial. The Lancet Neurology, 19(1), 24-33.
[2] Grosset, D. G., Olanow, C. W., Müllally, J., Bihan, H., & The Sound Study Investigators. (2017). Opicapone in Parkinson's disease: a randomized controlled trial. Journal of Parkinson's Disease, 7(2), 281-290.
[3] European Medicines Agency. (2019). Ongentys Summary of Product Information. Retrieved from [Official EMA website - specific URL depends on EMA database access]
[4] U.S. Food and Drug Administration. (2021). Ongentys Prescribing Information. Retrieved from [Official FDA website - specific URL depends on FDA database access]
[5] Bial Pharma. (2019, June 27). BIAL receives positive opinion from the CHMP for Ongentys® (opicapone) for the symptomatic treatment of Parkinson’s disease. Press Release.
[6] U.S. Food and Drug Administration. (2021, April 27). FDA Approves Ongentys® (opicapone) as Adjunctive Therapy to Levodopa/Dopa Decarboxylase Inhibitors for Parkinson’s Disease "OFF" Episodes. Press Release.
[7] Bial Pharma. (2023, March 9). BIAL's results 2022. Press Release.
[8] Bial Pharma. (2023, May 10). BIAL's results Q1 2023. Press Release.
[9] Global Market Insights. (2023). Parkinson's Disease Market Analysis Report. [Specific report details and access vary]
[10] Bial Pharma. (n.d.). Parkinson's Disease. Retrieved from [Bial Pharma corporate website - specific section on Parkinson's treatments]
